Clinical Emphasis, First-in-Human

Eric Aarntzen, MD, PhD
Radboud UMC; Nijmegen, Netherlands

Research Interests:

Dr. Aarntzen’s research focus is on characterizing the microenvironment in cancer and infectious diseases using ex vivo cell labelling approaches and multimodal imaging techniques. In May 2015, he co-developed the winning business plan during the Dutch Venture Challenge on spin-off possibilities of the patented multimodal PLGA-nanoparticle that will be used in this project to label lymphocytes in both mice and patients. Following up on this project, he was granted the JO RIMLS grant ‘Multimodal imaging of distinct immune cell populations with optimized nanoparticles’ in October 2016 and the Radboud Oncology Fund/KWF grant KUN2015-8106 ‘Tailored treatment in pancreatic cancer; predicting the heterogeneous behaviour of pancreatic cancer using non-invasive PET/CT imaging’ in February 2016.

Ferdia Gallagher, MD, PhD
University of Cambridge; Cambridge, UK

Research Interests:

Dr. Gallagher’s research focuses on oncological imaging methods and his laboratory develops new functional and molecular imaging approaches to detect cancer and early response to therapy, with the aim of translating these techniques into humans.

Keon Wook Kang, MD, PhD
Seoul National University; Seoul, South Korea

Research Interests:

Dr. Kang’s research focuses on in vivo molecular imaging and therapy of cancer using PET & nanoparticles. Particularly: 

  1. Clinical trials using angiogenesis PET for cancer
  2. Translational research using multifunctional nano-particles for optical/PET/MRI imaging
  3. In vivo cell trafficking of stem cells or immune cells using bioluminescence, fluorescence, radio-labeled technology
  4. Biodistribution, pharmacokinetics, and efficacy of nano drug delivery systems using in vivo imaging.

Fabian Kiessling, MD
University Hospital, RWTH Aachen University; Aachen, Germany

Research Interests:

Univ.-Prof. Dr. med. Fabian Kiessling is the head of The Institute for Experimental Molecular Imaging (ExMI) at the University Hospital Aachen and the Helmholtz Institute for Biomedical Engineering at RWTH Aachen University. ExMI focuses on the development of novel contrast agents, imaging techniques and therapeutic approaches to characterize and treat cancer, cardiovascular and inflammatory disorders.

Andrew M. Scott, MD

  1. University of Melbourne; Melbourne, Australia
  2. Olivia Newton-John Cancer Research Institute; Victoria, Australia
  3. Austin Health; Melbourne, Australia

Research Interests:

As a translational clinician-scientist, Dr. Scott’s research interests are focused on developing innovative strategies for targeted therapy of cancer with monoclonal antibodies as well as molecular imaging. His laboratory has been involved in the preclinical development and first‐in‐man trials of eight recombinant antibodies in cancer patients. His major research focus areas have been in defining and characterizing antigen and receptor targets for cancer therapy, signaling and metabolic pathways in cancer cells, antibody-based therapy and immune regulation of tumours, and molecular imaging of cancer.